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Abstract: The standard of care for treating ADHD is to use a psychostimulant as the ﬁ  rst line 
agent. Recent medical literature reports that approximately 70%–90% of patients with ADHD 
received some beneﬁ  t from a stimulant medication. Even though psychostimulants have a high 
rate of efﬁ  cacy, an estimated 30%–50% of children and adults may discontinue psychostimulants 
secondary to adverse effects or inadequate response. Guanfacine has been used for a number of 
years as an off label alternative to psychostimulants. This article reviews the current literature 
on the effectiveness of guanfacine in treating ADHD. It also introduces the preliminary data for 
guanfacine extended release and its effectiveness in decreasing the symptoms of ADHD.
Keywords: guanfacine, alpha adrenergic agonist, attention deﬁ  cit/hyperactivity disorder, 
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Introduction
Attention deﬁ  cit/hyperactivity disorder (ADHD) is one of the most commonly diag-
nosed psychiatric disorders in school aged children. The National Institute of Mental 
Health (NIMH) estimates that its prevalence is between 3% and 10%, with ADHD 
affecting approximately 2 million children in the United States (Biederman et al 2006; 
Lopez 2006). ADHD is diagnosed 2–3 times more often in boys than girls, and is 
commonly “co-morbid” with other mental disorders such as depressive and anxiety 
disorders, substance abuse, conduct disorder, and antisocial behaviors (NIMH). ADHD 
is associated with signiﬁ  cant psychiatric morbidity and functional impairment, includ-
ing disruptive behaviors and a loss in educational productivity. Children with untreated 
ADHD have higher than normal rates of accidents and injury (NIMH). According to the 
Center for Disease Control Center (CDC), the estimated cost attributable to ADHD is 
about US$3.5–4.0 billion annually due to its impact on education, health care, and the 
juvenile justice system. The annual medical cost of families who have a child diagnosed 
with ADHD is 2–3 times that of comparison families (Jenson et al 2005).
The short-term efﬁ  cacy of psychostimulants in the treatment of ADHD has been 
well demonstrated, but an estimated 30%–50% of treated children and adults never-
theless discontinue psychostimulants due to adverse effects or inadequate response. 
(Biederman et al 2006). Warnings by the Food and Drugs Administration (FDA) that 
psychostimulants may be associated with sudden death and serious cardiovascular 
adverse events and the suspension of Adderall® (Shire) distribution by Canadian 
authorities because of these same concerns have generated unease among both 
consumers and professionals (www.fda.gov). Atomoxetine, the ﬁ  rst non-stimulant 
approved by the FDA for the treatment of ADHD, has received a “black box warning” 
from the FDA due to reports of increased suicidal thoughts and behaviors. Conse-
quently, clinicians may explore alternative medications and approaches toward the 
treatment of ADHD.Neuropsychiatric Disease and Treatment 2008:4(3) 500
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This article reviews of the safety and efficacy of 
guanfacine for the management of youth with ADHD, includ-
ing available but as yet unpublished data regarding guanfacine 
extended release (GXR) (Tenex ER®; Shire)
Methods
A review of the literature was done using PubMed. The 
search terms initially used were: guanfacine, attention, 
hyperactivity, alpha agonist, children, and ADHD. Limiting 
articles only to studies on children ages 0–18 years old was 
initially used, but this caused the results to be too narrow and 
speciﬁ  c. The ﬁ  nal search terms that yielded the most articles 
with pertinence to guanfacine and ADHD were “guanfacine 
and attention.” There were 74 articles and 44 of them were 
reviewed. Articles that were excluded were mostly animal 
models which met the search criteria because of key words, 
but were not relevant to the topic of this article. Also there 
were a few articles related to ADHD and other medications 
which were included in the search result, but were not suit-
able. The ﬁ  nal articles which were reviewed consisted of 
relevant human and animal trials of guanfacine, open label 
studies, chart reviews, and placebo controlled trials. Also, 
some information about Tenex ER® was received from Shire 
in the form of poster presentations.
Mechanism of action
Guanfacine, like clonidine, is an alpha 2-agonist (α). 
α2-agonists stimulate the α2 adrenergic receptor (AR) in 
the brain (Scahill et al 1999). There are 5 general classes 
of adrenergic receptors, α1, α2, β1, β2, and β3 (MacDonald 
et al 1997). Within these general classes there are subtypes 
of receptors; the α2 receptor has 3 subtypes: the α2A, the α2B, 
and the α2C (MacDonald et al 1997). Clonidine stimulates all 
3 subtypes, as well as the imidazoline I1 receptor (Coupry 
et al 1989; Uhlen et al 1994), whereas guanfacine more 
selectively interacts with the α2A subtype (Uhlen et al 1994). 
The α2A subtype can be found both presynaptically on NE 
neurons, and postsynaptically on nonNE neurons (Aoki et al 
1998; Wang et al 2007). Indeed, the majority of α2A receptors 
are actually postsynaptic to NE neurons (U’Prichard et al 
1979). Stimulation of the presynaptic α2 receptors reduces 
NE release from terminals and decreases the ﬁ  ring of NE 
cell bodies in the locus coeruleus (LC). Clonidine is 10 times 
more potent than guanfacine at these presynaptic actions 
(Engberg and Eriksson 1991), while guanfacine appears to be 
more potent at postsynaptic receptors (Arnsten et al 1988). 
The therapeutic properties of guanfacine in ADHD arise 
from actions in the prefrontal cortex (PFC). The PFC has 
a signiﬁ  cant role in executive functions, which includes 
regulation of attention, planning, impulse control, and 
processing (Arnsten and Li 2005). Dysfunction with these 
areas causes forgetfulness, distractibility, impulsivity, impair-
ment in working memory, and mental ﬂ  exibility (Arnsten 
and Li 2005). Disruption in the PFC, and its projections to 
the striatum and cerebellum, are also associated with ADHD 
symptoms (Castellanos et al 2002; Seidman et al 2006). Inat-
tention, impulsivity, and distractibility are all core features 
of ADHD.
Guanfacine enhances prefrontal cortical regulation 
of attention and impulse control by strengthening PFC 
functions. In animal studies, infusion of guanfacine 
directly into the PFC improves performance of PFC tasks 
(Mao et al 1999; Ramos et al 2006). This improvement 
can be observed at the cellular level as well, where 
electrophysiological recordings show that guanfacine 
strengthens the connections between PFC networks, 
increasing network ﬁ  ring (Wang et al 2007). PFC neuronal 
networks interconnect via glutamate synapses on dendritic 
spines. Guanfacine appears to strengthen PFC network 
connections by stimulating postsynaptic α2A receptors on 
the dendritic spines of PFC pyramidal cells, the sites of 
PFC network connections (Wang et al 2007). Stimulation 
of these α2A receptors with NE or guanfacine inhibits local 
cAMP production, which in turn closes nearby ion channels 
that make the membrane “leaky”. Closing of these channels 
strengthens glutamatergic synaptic inputs onto the spine, 
increasing network ﬁ  ring and allowing greater control over 
attention and behavior (Wang et al 2007). This strengthening 
of PFC neuronal ﬁ  ring is reﬂ  ected in greater cerebral blood 
ﬂ  ow to the PFC in monkeys and humans (Avery et al 2000; 
Swartz et al 2000). 
Conversely, blocking α2 receptors in PFC with yohim-
bine weakens PFC functions and induces a proﬁ  le similar 
to ADHD. Yohimbine causes a collapse in PFC network ﬁ  r-
ing, silencing PFC neurons (Wang et al 2007). Infusions of 
yohimbine into the monkey PFC weaken working memory 
and impulse control, and induce locomotor hyperactivity, 
similar to the symptoms of ADHD (Ma et al 2003, 2005). 
Impaired PFC function is also observed in ADHD patients 
with inadequate NE due to genetic alterations in dopamine 
beta hydroxylase, the synthetic enzyme for NE (Bellgrove 
et al 2006; Kieling et al 2008).
The PFC is one of the few intelligent inputs to the LC, 
and thus guanfacine strengthening of PFC function may also 
enhance regulation of LC noradrenergic release through-
out the brain (Sara and Herve-Minvielle 1995; Arnsten Neuropsychiatric Disease and Treatment 2008:4(3) 501
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et al 1996). With optimal PFC regulation, the LC ﬁ  res to 
relevant but not irrelevant stimuli (Aston-Jones et al 2000). 
In contrast, without this informed regulation, the LC appears 
to ﬁ  re to distractors (Aston-Jones et al 2000). The PFC also 
regulates attention and behavior through massive projections 
to the sensory and motor cortices, the basal ganglia, and 
cerebellum (Goldman-Rakic 1987). Thus, strengthening PFC 
networks optimizes orchestration of brain function.
Pharmacokinetics
Guanfacine hydrochloride (Tenex®; Shire) was approved by 
the FDA for use in adult hypertensive patients in 1986. It is 
N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride. 
It also has off label use for ADHD and tics. Guanfacine is 
absorbed in the gastrointestinal track with almost 100% bio-
availability (Cornish 1988). Its half-life is 17 hours (range 
10–30 hours) in adults and 13–14 hours in children and adoles-
cents. Its peak time in the serum is 1–4 hours. The area under 
the concentration-time curve (AUC) increases linearly with 
dosage. Approximately 30%–50% of guanfacine is eliminated 
in the urine unchanged and the remainder is metabolized by 
the liver CYP2C9; CYP2C19. Phenytoin and phenobarbital 
can induce the metabolism of guanfacine (Sorkin and Heel 
1986; Cornish 1988; Fuller and Sajatovic 2002).
Elimination half-life is not signiﬁ  cantly changed with 
renal impairment. Serum drug levels of guanfacine are only 
slightly increased in patients with renal dysfunction compared 
to patients with normal renal function (Cornish 1998). This 
is thought to be caused by increased non-renal elimination, 
most likely performed by the liver (Cornish 1988; Sorkin and 
Heel 1986). The guanfacine-to-creatinine clearance ratio is 
greater than 1, which would suggest that tubular secretion 
of the drug occurs. The drug is approximately 59%–100% 
bound to plasma proteins and not inﬂ  uenced by plasma 
concentration (Cornish 1988; Mosqueda-Garcia 1990). The 
volume of distribution in the body is 6 L/kg (Cornish 1988), 
which suggests a high distribution of drug to the tissues.
The pharmaceutical company Shire has been developing 
a guanfacine extended release formulation (GXR) to help 
with compliance by providing once-daily dosing. An initial 
phase 1 randomized, open-labeled, single-dose, crossover 
pharmacokinetic study was done in 52 healthy adults, ages 
18–55. GXR half-life is 16.6–17.5 hours. The pharmaco-
kinetics of GXR is generally linear for dosage from 2 to 4 
mg, but there is a less than 2-fold increase between the 1–2 
mg doses. This seems contrary to what would be expected. 
A pharmacokinetic study on GXR showed that the plasma 
concentration was higher in children than in adolescents. 
GXR has a linear pharmacokinetics with multiple daily doses 
(Boellner et al 2007).
Clinical studies guanfacine 
immediate release (GIR)
One of the ﬁ  rst open trials of GIR by Hunt in 1995, as a 
treatment alternative for ADHD, showed promising results. 
The studies had 13 subjects, ages 4–20 years old, who 
received guanfacine for 4 weeks (Hunt et al 1995). There was 
a signiﬁ  cant decrease in the post-medication Conner Parental 
Ratings Scale (CPRS) score of the subjects. The results of 
the study may be ﬂ  awed because subjects were receiving 
other non-study medication which could greatly impact the 
ﬁ  nal results of the study. This was not clearly discussed in 
the study (Cohn and Caliendo 1997).
In a follow up open label trial for ADHD and tics, by 
Chappell, with 10 subjects, ages 8–16 years old, 6 subjects 
(60%) were medication naïve and 4 (40%) had a prior history 
of failing or not tolerating a trial of clonidine. The study had 
mixed results. Even though the overall decrease in CPRS was 
statically insigniﬁ  cant, 4 (40%) subjects, had moderate-to-
marked improvement in CPRS. The Continuous Performance 
Test (CPT) showed signiﬁ  cant improvement in both errors of 
omission and commission in all the subjects (Chappell et al 
1995). Two (20%) subjects dropped out because of persistent 
headaches and sedation. Two (20%) patients were on other 
non-study medications and 1 (10%) had comorbid OCD. The 
methodology of the study was weak because of the variability 
of follow up between subject and length of time in the clinical 
trial (Cohn and Caliendo 1997).
An open label trial of guanfacine to treat ADHD was 
later done using a population within the placebo control 
trial from the Tics Disorder Clinic of Yale Child Study 
Center. There were 25 subjects in all, 4 who did not meet the 
severity for a different placebo-controlled trial, 8 declined 
to participate in this same trial, and 13 were placebo non-
responders for this trial. Their ages ranged from 7 from 
16 years. CPRS, Conner’s Teacher’s Rating Scale (CTRS) 
and the Yale Global Severity Scale (YGTSS) were used to 
rate the severity of the patients’ ADHD and tics pre and post 
medication. Seven (28%) participants dropped out due to 
lack of efﬁ  cacy. The rating score from their last evaluation 
was carried forward. On the parent rating scales there was a 
27% decrease in the hyperactivity rating and a 36% decrease 
in the teacher hyperactivity/impulsivity score. The overall 
tic score decreased by 39. These results were consistent with 
the open label trials and the one placebo-controlled trial 
(Boon-yasidhi et al 2005).Neuropsychiatric Disease and Treatment 2008:4(3) 502
Strange
A recent 8-week study with guanfacine for children with 
pervasive development disorder (PDD) and hyperactivity was 
conducted by the RUPP Autism Network (Scahill et al 2006). 
There were 25 subjects, all who had failed a larger placebo-
controlled trial with methylphenidate. Their ages were 5–14 
years. On the Clinical Global Impression (CGI) Severity scale 
their scores for ADHD were at least moderate. There was a 
40% decrease in the hyperactivity subscale of the Aberrant 
Behavior Checklist per parent rating and a 27% decrease 
for the teachers as well. The Swanson, Nolan, and Pelham 
checklist (SNAP-IV) parental rating showed a 41% decrease 
while the teacher scale was 20%. Of the 25 subjects, 12 were 
“Much improved” or “Very Much” Improved on the SNAP-IV. 
Five (20%) subjects withdrew from the study; 2 because of 
lack of efﬁ  cacy and 3 because of irritability. This study shows 
that guanfacine has some efﬁ  ciency in symptoms reduction 
of ADHD. Since these subjects have already failed a trial 
with methylphenidate, their ADHD symptoms may be more 
resistant to treatment in general. Children with the diagnosis of 
PDD are typically more sensitive to the side effects of medica-
tions and often are more refractory to pharmacotherapy. If the 
subjects who were accepted had not already failed a trial with 
a stimulant, there potentially could have had a more robust 
response to the guanfacine (Scahill et al 2006).
In 2001, Scahill was the ﬁ  rst placebo controlled trial 
for guanfacine treating children with ADHD and tic dis-
orders. There were 34 participants who were randomized 
into a placebo or medication group, 17 and 17. The CGI, 
CPRS and CTRS, the Yale Global Tic Severity Scales 
(YGTSS), and the CPT were used prior to initiation of 
medication and at the end of the clinical trial. After 8 
weeks there was a 37% decrease in ADHD symptoms in 
the guanfacine group versus 8% for the placebo group. 
CGI scores rated 9 (53%) of the guanfacine group were 
very much improved or much improved. Tics decreased by 
31%, compared to a 0% change by the placebo group. The 
CPT had a 22% and 17% decrease in the commission and 
omission errors in the guanfacine group vs 29% and 31% 
increase in the placebo group. Parent rates did not show 
signiﬁ  cant difference between the placebo and treatment 
group. The effect size (ES) was 0.65, which is statistically 
signiﬁ  cant. The ES is calculated by mean change in score 
for the guanfacine group minus the change for the placebo, 
divided by the mean standard deviation for endpoint of the 
study (see Table 1). The mean improvement of guanfacine 
is 36%, which is signiﬁ  cantly less than that of stimulants, 
which is usually 50%–60%. The power of the study was 
small as well (Scahill et al 2001).
The single comparative study for adults with ADHD 
showed that guanfacine was comparable to dextroamphet-
amine (DAMP). There were 17 subjects, ranging from 21 to 
57 years old. They were all diagnosed by meeting DSV-IV 
criteria for ADHD from 7 years old on. They all were above 
the 93rd percentile for ADHD symptoms. All subjects had a 
2-week trial of placebo, guanfacine and DAMP with a 4-day 
wash out period between each trial. They were administered 
the DSM-IV ADHD Behavior Checklist for Adults, the 
Copeland Symptom Checklist for Adult Attention Deﬁ  cit, 
the Beck Depression Inventory (BDI), the Hamilton Rat-
ing Scale for Anxiety (HRSA), the Yale-Brown Obsessive 
Compulsive Scale (Y-BOCS), the Stroop Color-Word 
Interference Test, and the Control Oral Word Association 
Test at baseline and at the end of each 2-week trial. Both 
DAMP and guanfacine showed a signiﬁ  cant improvement 
on the ADHD Behavioral Checklist for Adults, but were not 
statistically different from one another. On the Copeland 
scale both drugs showed some improvement from placebo, 
but it was statistically insigniﬁ  cant. Even though both 
guanfacine and DAMP showed improvement from placebo 
attention and impulsivity, all subjects stated that DAMP 
was the only medication that improved motivation (Taylor 
and Russo 2001).
Clinical studies of GXR
Shire funded a multi-site phase 3 placebo-controlled double 
blind trial of GXR involving 345 children and adolescents 
ranging in age from 6 to 12 years. Patients were randomized 
into 4 groups: placebo, 2 mg, 3 mg, and 4 mg. Each group 
was titrated up to their maximum dose, starting at 2 mg, over 
3 weeks. The ADHD-RS-IV was the primary measure and the 
secondary measures were the CGI-I, CPRS, and CTRS. After 8 
weeks the change in subjects’ hyperactivity/impulsivity scores 
on the ADHD-RS-IV adjusted for placebo were –3.68 (2 mg), 
–3.58 (3 mg), and –5.62 (4 mg) (p   0.001 for all comparisons) 
and for the inattentiveness subscale were –3.74 (2 mg), –3.94 
(3 mg), and –4.26 (4 mg) (p   0.01 for GXR 2 mg and 3 mg; 
p   0.001 for GXR 4 mg). On the CGI the subjects improved 
at the endpoint 25.6% (placebo), 56.0% (2 mg), 50.0% (3 mg), 
and 55.6% (4 mg). The most common treatment emergent 
adverse events were somnolence (GXR 32% vs placebo 4%), 
headache, fatigue, and upper abdominal pain. Forty subjects 
withdrew from the GXR group versus one from placebo. While 
the GXR subjects had decreased diastolic and systolic blood 
pressures, the drug was well tolerated. Although the advantage 
over placebo was signiﬁ  cant, the size of the effect could not be 
calculated due to insufﬁ  cient data. The standard deviations are Neuropsychiatric Disease and Treatment 2008:4(3) 503
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not given, nor are the data from the pre or post measurement 
given (Melmed et al 2006) (see Table 1).
Adverse reaction
Similar to clonidine, an α-agonist, the major side effects of 
GIR and GXR are sedation and fatigue. The rate of sedation 
for the studies ranged from 16% to 35% and fatigue from 
12% to 60%. Dry mouth, headaches, stomachaches, sleep 
disturbance, and irritability were prominent as well (Cornish 
1988; Chappell et al 1995; Hunt et al 1995; Scahill et al 1999, 
2001; Boon-yashidhi et al 2005). In general the medication 
was fairly well tolerated. Even though GIR is often used as a 
blood pressure medication, there were not signiﬁ  cant events 
of orthostatic hypotension or bradycardia. The subjects’ 
headaches and dizziness were not directly associated with 
any changes in blood pressure. With each dose increase of 
GXR, there is greater sustained decrease in both systolic and 
diastolic blood pressure and pulse. No subject had a QRS 
interval  120 msec and/or a QT interval   480 msec increase 
from baseline ECG assessment (Melmed et al 2006).
Hypomania, possibly with hallucinations (Boreman and 
Arnold 2003) is a rare, but possible side effect. If a patient has 
bipolar or mood disorder, they should be monitored carefully 
(Horrigan and Barnhill 1998).
Administration
Dosing for GIR and GXR is 1–4 mg per day. GIR is divided 
bid or tid, while GXR is a single dose per day. Because of 
the possibility of sedation with GIR, it is best to start at 
0.25–0.5 mg at bedtime for 3–4 days and then increase to 
0.5 mg in the morning and night. Dosage can be increased 
by 0.5 mg every 3–4 days (Chappell et al 1995; Hunt et al 
1995; Scahill et al 2001, 2006; Taylor and Russo 2001; 
Posey et al 2004; Boon-yasidhi et al 2005). Most children 
are usually prescribed 0.5–2 mg bid-tid (Arnold 2002). For 
GXR, All subjects were started on 1 mg and titrated up by 
1 mg per week, to a maximum of 4 mg. This study does not 
specify whether 4 mg will be the recommended maximum 
daily dosage for children (Melmed et al 2006).
Screening for any cardiac problems or family his-
tory of cardiac complications is essential (Newcorn et al 
1998; Pliszka 2007). Blood pressure and pulse rate were 
monitored regularly in all studies for ADHD, with the 
exception of the Chappell and Hunt primary studies in 
1995. There were no signiﬁ  cant sustained changes in 
systolic or diastolic blood pressure or pulse with GIR, but 
it was signiﬁ  cant in the GXR study. It is unclear whether 
this difference is due to the lack of an adequate number 
of subjects for the GIR studies. Since hypotension and 
bradycardia can be an adverse effect of the medication, 
regularly monitoring blood pressure and pulse is important 
(Pliszka 2007).
In an article about α2 adrenergic agonist, Newcorn et al 
recommends an electrocardiogram (ECG) at baseline and 
with increased dosage of Clonidine (Newcorn et al 1998). 
In the most recent studies, ECGs were taken at baseline 
Table 1 Effect size of placebo-controlled trials of ADHD medications
Placebo-controlled  Medication  Number of subjects  Effect size  Assessment tools
trial   given  medication
Scahill et al 2001  GIR  34  0.88  ADHD RS-IV(pm), CGIS, CPRS, and CTRS
Melmed et al 2006  GXR  345  0.79 (0.13–  ADHD RS-IV(pm), CGIS, CPRS, and CTRS
     0.17  mg/kg)
Wolraich et al 2001  OROS MPH  94  1.05  IOWA Conners Ratings Scale(pm), SNAP-IV,
        (Teacher and Parent for both)
Wolraich et al 2001  IR MPH  94  1.02  IOWA Conners Ratings Scale(pm),
        SNAP-IV (Teacher and Parent for both)
Michelson et al 2002  ATX  85  0.71  ADHD RS-IV(pm), CGIS, CPRS, and CTRS
Weiss et al 2005  ATX  101  0.63  ADHD RS-IV(pm), Academic Performance
        Rating Scale, Academic Performance
        Rating Scale, The Social Skills Rating System-
        Teacher, The Conners Global Index-Teacher,
       CGI,  CPRS
Conners et al 1996  Buproprion  61  0.16   CPRS(pm), CTRS(pm), CGIS, Continuous
     (parent  scale)  Peformance  Test
     0.27
     (teacher’s  scale)
Abbreviations: ATX,  atomoxetine; G, guanfacine; IR, immediate release; XR, extended release; MPH, methylphenidate; OROS®, MPH (Concerta); (pm), primary outcome measure.
Note: ADHD Rating Scale-IV (ADHD RS-IV), Clinical Global Impression Scale (CGIS), Conners Parental Rating Scales (CPRS),  Conners Teacher Rating Scales (CTRS), 
Swanson, Nolan, and Pelham Checklist, Version IV ( SNAP IV).Neuropsychiatric Disease and Treatment 2008:4(3) 504
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(Scahill et al 2001; Swearingen et al 2007). In the 2007 
practice parameter for ADHD published by the American 
Academy of Child and Adolescent Psychiatry, an ECG is 
not recommended for clonidine nor for guanfacine (Pliszka 
2007). The guidelines recommend a baseline EKG for 
patients who have preexisting heart disease or symptoms 
suggesting signiﬁ  cant cardiovascular disease. The symp-
toms include dizziness, chest pain, fainting, palpations, and 
exercise intolerance. Caution is still warranted with the use 
of α2 adrenergic agonist (Pliszka 2007).
GIR, like clonidine, can have a withdrawal syndrome 
with abrupt cessation. Symptoms include increased blood 
pressure, headache, tremor, restlessness, and nausea. This is 
rare, approximately 3% compared to 50%–80% with clonidine. 
The difference in the withdrawal rates may be explained 
by guanfacine’s longer half-life. Most subjects have mild 
sympathetic hyperactivity (Sorkin and Heel 1986; Cornish 
1988). Standing blood pressures may increase 33 mmHg, 
systolic, and 16 mmHg, diastolic, over pretreatment baseline 
(Sorkin and Heel 1986). A placebo-controlled study using GXR 
on 45 healthy adults, age 19–24 years, showed no clinically 
signiﬁ  cant vital sign or ECG changes in subjects who abruptly 
stopped GXR versus being tapered off (Kisicki et al 2007).
Discussion
To date there is still only one placebo controlled trial for 
GIR. The reduction in ADHD symptoms for this guanfacine 
trial is clinically signiﬁ  cant, but it is not as robust as with 
stimulants. Two-thirds of the patients in Scahill’s study had 
prior treatment failure with psychostimulants. A number 
of these patients had co-morbid diagnoses as well. These 
patients may have been more refractory to treatment which 
could account for the lower response rate and reduction in 
symptoms (Scahill et al 2001).
The 37% improvement in ADHD symptoms from Scahill’s 
placebo-control study is consistent with percentage improve-
ment in the open label trials for GIR. The percentage change 
from teacher and parents baseline ratings for hyperactivity 
ranges from 20%–36.1% and 26%–41% (Boon-yasidhi et al 
2005; Scahill et al 2006). Within all the trials, GIR seems to 
work best on inattentive, impulsive and hyperactive symptoms 
(Posey et al 2004; Biederman et al 2006). For children with co-
morbid tics, guanfacine signiﬁ  cantly decreased the prevalence 
of tics (Chappell et al 1995; Boon-yasidhi et al 2005).
The phase 3 trials by Shire for GXR represent the ﬁ  rst 
placebo-controlled trial for guanfacine in which there is a sta-
tistically signiﬁ  cant number of subjects. None of the subjects 
in the study have any other co-morbid psychiatric diagnosis 
with the exception of oppositional deﬁ  ant disorder. There is 
a statistical difference in the reduction in symptoms between 
the placebo and the GXR group (Melmed et al 2006). This 
study suggests the efﬁ  cacy of guanfacine in treating ADHD 
symptoms with adequate power and study design.
Guanfacine has a longer half-life than clonidine and 
appears to have fewer problems with sedation, changes in blood 
pressure and pulse (Newcorn et al 1998; Lopez 2006). GXR 
can be given once per day which may help with compliance. 
Dry mouth, sedation, fatigue, and headache are still signiﬁ  cant 
side effects which may adversely impact the patient.
Even though psychostimulants are still the ﬁ  rst line treat-
ment for ADHD and atomoxetine is the only non-stimulant 
approved for ADHD, guanfacine may be a good alternative 
for children with comorbid ADHD and tic (Chappell et al 
1995; Scahill et al 2001). For children who may not be receiv-
ing enough of a beneﬁ  t from psychostimulants and may have 
trouble with insomnia, there is a possibility of using guan-
facine in conjunction with a psychostimulant to help treat 
their ADHD symptoms and sleep disturbances aggravated by 
the psychostimulant (Scahill et al 2001). Decreased appetite 
and gastrointestinal events are a common side effect for 
atomoxetine (Weiss et al 2005). For children with predomi-
nantly impulsivity and hyperactivity, or for children who are 
unable to tolerate the side effects from either atomoxetine or 
psychostimulants, guanfacine may be a possible alternative 
(Posey et al 2004; Biederman et al 2006).
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